20406-84-2

Upstream product

• 28734-85-2 3-benzyl-2,3-dihydropyrimidin-4(1H)-one 
• 77-78-1 dimethyl sulfate 
• 615-77-0 1-methyluracil 
• 100-39-0 benzyl bromide 
• 253142-23-3 3-benzyl-2-methoxy-4-pyrimidinone 

Relevant academic research and scientific papers

INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS

This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.

HSAB driven chemoselectivity in alkylation of uracil derivatives. A high yielding preparation of 3-alkylated and unsymmetrically 1,3-dialkylated uracils

A qualitative hardness scale (N134) has been found for the conjugated bases of 2-methoxy-4(3H)-pyrimidinones 1-3 and applied to high yielding chemoselective N3 methylation, ethylation and benzylation reactions. Removal of the 2-methoxy group followed by a second alkylation affords unsymmetrically 1,3-disubstituted uracils.